Literature DB >> 7954422

Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.

S W Johnson1, P A Swiggard, L M Handel, J M Brennan, A K Godwin, R F Ozols, T C Hamilton.   

Abstract

We examined several aspects of platinum-DNA adduct formation and repair in cisplatin-sensitive and -resistant human ovarian cancer cell lines. The formation of cisplatin-interstrand crosslinks (ICLs) was measured in five DNA sequences by renaturing agarose gel electrophoresis. There were considerable differences (up to 4-fold) in ICL levels in these DNA sequences following a 4-h incubation with cisplatin; however, the pattern of ICL formation did not depend on whether the region was transcriptionally active or gene encoding. Incubation of purified DNA with cisplatin yielded an ICL pattern with considerably less variability between the regions examined. Cisplatin ICL and total DNA platination levels were significantly higher (up to 20- and 40-fold, respectively) in cisplatin-resistant cell lines as compared to the parental, cisplatin-sensitive cell line at equivalent levels of cisplatin cytotoxicity. Under cisplatin exposure conditions which yielded similar initial levels of sequence-specific ICLs, the cisplatin-resistant cells removed up to 2.5 times more ICLs by 12-h posttreatment than the parental cell line. Increased removal of the individual platinum-deoxyribonucleosides of platinum-DNA adducts was also observed in the highly resistant C200 cell line as determined by high performance liquid chromatography separation and quantitation by atomic absorption spectrometry. These results indicate that DNA repair contributes significantly to cisplatin resistance and that increased DNA-damage tolerance may also be a component of the resistance phenotype in this model system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954422

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.

Authors:  Sang Soo Hah; Paul T Henderson; Kenneth W Turteltaub
Journal:  Bioorg Med Chem Lett       Date:  2010-03-07       Impact factor: 2.823

2.  A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor.

Authors:  Eunsuk Kim; Peter T Rye; John M Essigmann; Robert G Croy
Journal:  J Inorg Biochem       Date:  2008-10-26       Impact factor: 4.155

Review 3.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

4.  Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Mike R Wilson; Nian Tong; Carrie O'Connor; Mohammad Karim; Lisa Polin; Adrianne Wallace-Povirk; Kathryn White; Juiwanna Kushner; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-04-27       Impact factor: 7.446

5.  Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.

Authors:  M Yamada; E O'Regan; R Brown; P Karran
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

6.  Immunofluorescent assay of ERCC1 and estimation of clinical significance of the protein expression in ovarian cancer tissue.

Authors:  T A Bogush; E A Dudko; A V Semakov; E A Bogush; A S Tjulandina; V T Zarkua; S A Tjulandin; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2014-08-30       Impact factor: 0.788

7.  Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.

Authors:  Zhanjun Hou; Leda Gattoc; Carrie O'Connor; Si Yang; Adrianne Wallace-Povirk; Christina George; Steve Orr; Lisa Polin; Kathryn White; Juiwanna Kushner; Robert T Morris; Aleem Gangjee; Larry H Matherly
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

Review 8.  Biomarkers of head and neck cancer, tools or a gordian knot?

Authors:  Evangeli S Lampri; Georgios Chondrogiannis; Elli Ioachim; Anna Varouktsi; Antigoni Mitselou; Aggeliki Galani; Evangelos Briassoulis; Panagiotis Kanavaros; Vasiliki Galani
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Jordyn Ginter; Sahithi Pamarthy; Safaa A Ibrahim; Mukesh K Jaiswal; Corina Sandulescu; Ramayee Periakaruppan; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2016-01-29       Impact factor: 6.603

10.  Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer.

Authors:  Akaash K Mishra; Silvana S Dormi; Alaina M Turchi; Derek S Woods; John J Turchi
Journal:  Biochem Pharmacol       Date:  2014-11-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.